Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Phytomedicine ; 94: 153794, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34775362

RESUMEN

BACKGROUND: Moutan radicis cortex (MRC) and Cinnamomi ramulus (CR) are commonly used in eastern Asian traditional medicine to treat various diseases including cerebrovascular and cardiovascular, and have wide spectrum of pharmacological activities. However, the effect against laser-induced choroidal neovascularization (CNV) of extract of MRC and CR (1:1) (MRCCR) has not yet been studied. PURPOSE: Our aim was to investigate the inhibitory effect of MRCCR on pathological CNV in laser-treated Brown-Norway (BN) rats. METHODS: MRCCR (60, 90 mg/kg) was orally administered twice per day for 15 days from the day of CNV formation in laser-treated BN rats. Effects of MRCCR or its constituents on cell migration, tube formation, hyperpermeability and phosphorylation of FAK/p38 MAPK were confirmed in humane retinal microvascular endothelial cells or human retinal pigment epithelial cells. RESULTS: MRCCR significantly reduced the CNV lesions areas and the extent of fluorescein leakage. MRCCR and its constituents such as ellagic acid, paeonol or gallic acid decreased cell migration, tube formation or hyperpermeability. MRCCR inhibited the phosphorylation of FAK and p38 MAPK. CONCLUSION: Combining the oral MRCCR and intravitreal injection of anti-VEGF medicine may result in a more potent therapeutic effect and consequently bring the reduction in eye injection numbers for patients with wet AMD.


Asunto(s)
Neovascularización Coroidal , Animales , Neovascularización Coroidal/tratamiento farmacológico , Modelos Animales de Enfermedad , Células Endoteliales , Angiografía con Fluoresceína , Humanos , Rayos Láser , Extractos Vegetales/farmacología , Ratas , Ratas Endogámicas BN , Factor A de Crecimiento Endotelial Vascular
3.
BMC Complement Altern Med ; 13: 251, 2013 Oct 03.
Artículo en Inglés | MEDLINE | ID: mdl-24090434

RESUMEN

BACKGROUND: Accumulating evidences suggest that aldose reductase (AR) inhibitors and advanced glycation end product (AGE) formation inhibitors may prevent chronic hyperglycemia-induced long-term complication in diabetes. Transforming growth factor-beta1 (TGF-ß1) plays an important role in the development of diabetic nephropathy. Allium species have been utilized in folk medicine throughout the world for the treatment of various physical disorders. However, the benefits of Allium victorialis (A. victorialis) against diabetic complications, especially nephropathy, have yet to be explored. In the present study, we investigated the protective effect of the compounds isolated from A. victorialis leaf on diabetic nephropathy. METHODS: In vitro AR activity, AGEs formation, and AGE-receptor for AGEs (RAGE) binding in human RAGE (hRAGE)-overexpressing cells were tested. High glucose-induced transforming growth factor-beta1 (TGF-ß1) expression was also examined in mouse kidney mesangial cells (MMCs) cultured under high glucose. RESULTS: Of the isolated eight compounds from A. victorialis leaf extracts tested, quercitrin exhibited the most pronounced inhibitory effects on AR activity (IC50 value of 0.17 µM) and AGEs formation (IC50 value of 4.20 µM). Furthermore, quercitrin disrupted AGE-RAGE binding in a concentration-dependent manner in hRAGE-overexpressing cells. Additionally, of the eight compounds tested, ferulic acid significantly reduced high glucose-induced TGF-ß1 expression and secretion in MMCs. CONCLUSIONS: Our results suggest that active compounds isolated from A. victorialis leaf exhibit inhibitory effects on AR activity in rat lenses and AGE formation. Further, ferulic acid reduces TGF-ß1 mRNA expression and secretion in MMCs under diabetic conditions. Thus, A. victorialis is a good candidate for the development of treatments for diabetic nephropathy.


Asunto(s)
Aldehído Reductasa/metabolismo , Allium/química , Productos Finales de Glicación Avanzada/metabolismo , Células Mesangiales/efectos de los fármacos , Extractos Vegetales/farmacología , Factor de Crecimiento Transformador beta1/metabolismo , Animales , Glucosa/metabolismo , Cristalino/efectos de los fármacos , Cristalino/metabolismo , Células Mesangiales/metabolismo , Ratones , Extractos Vegetales/química , Hojas de la Planta/química , Ratas , Ratas Sprague-Dawley
4.
Assay Drug Dev Technol ; 9(5): 503-13, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21561378

RESUMEN

Glycogen synthase kinase-3ß (GSK-3ß), a serine/threonine kinase also known as tau protein kinase I, has been implicated in the pathogenic conditions of Alzheimer's disease. Many investigators have focused on GSK-3 inhibitor as a therapeutic drug. In this study, we established a cell-based assay for the screening of novel GSK-3ß inhibitors. For this purpose, four-repeat tau cDNAs were stably expressed in human embryonic kidney 293 (HEK293) cells (HEK293-Tau). The proliferation of HEK293-Tau cells was no different from that of HEK293 cells, as measured by the bromodeoxyuridine enzyme-linked immunosorbent assay (BrdU ELISA). The concentration-dependent reduction of tau phosphorylation by GSK-3 inhibitors, LiCl, Chir98023, and SB415286, was examined by immunoblot analysis and Tau ELISA (in situ ELISA). Highly consistent data were obtained, suggesting that this novel ELISA method is highly reproducible. Using this ELISA strategy, we isolated a few candidate compounds, including compounds 114 and 149, from several hundreds of synthetic agents and demonstrated that such candidates protect nerve growth factor-differentiated PC12 cells against amyloid-ß-induced cell death. These data indicate that this Tau ELISA method in HEK293-Tau cells may be a suitable cell-based assay system to screen for GSK-3ß inhibitors.


Asunto(s)
Enfermedad de Alzheimer/enzimología , Descubrimiento de Drogas/métodos , Inhibidores Enzimáticos/farmacología , Glucógeno Sintasa Quinasa 3/antagonistas & inhibidores , Proteínas tau/genética , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Aminofenoles/análisis , Aminofenoles/metabolismo , Aminofenoles/farmacología , Aminofenoles/toxicidad , Animales , Técnicas de Cultivo de Célula , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/análisis , Inhibidores Enzimáticos/metabolismo , Inhibidores Enzimáticos/toxicidad , Ensayo de Inmunoadsorción Enzimática , Glucógeno Sintasa Quinasa 3/análisis , Glucógeno Sintasa Quinasa 3/fisiología , Células HEK293 , Humanos , Imidazoles/metabolismo , Imidazoles/farmacología , Immunoblotting , Maleimidas/análisis , Maleimidas/metabolismo , Maleimidas/farmacología , Maleimidas/toxicidad , Terapia Molecular Dirigida , Fármacos Neuroprotectores/análisis , Fármacos Neuroprotectores/metabolismo , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/toxicidad , Células PC12 , Fosforilación/fisiología , Plásmidos , Piridinas/metabolismo , Piridinas/farmacología , Pirimidinas/metabolismo , Pirimidinas/farmacología , Ratas , Proteínas tau/metabolismo
5.
Bioorg Med Chem ; 14(14): 4803-19, 2006 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-16580210

RESUMEN

In order to develop pure antiestrogens, a series of 7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman and 7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman derivatives with sulfoxide containing side chains at the 4-position were designed, synthesized, and evaluated. Among them, compounds 14b and 24b functioned as pure antiestrogens with the ability to downregulate ER, and their in vitro and in vivo antiestrogen activities were similar to those of ICI182,780. In addition, the structure-activity relationship indicated that the (3RS,4RS)-configuration between the 3- and 4-position, the methyl group at the 3-position, the 9-methylene chain between the scaffold and the sulfoxide moiety, and the terminal perfluoroalkyl moiety play an important role in increasing estrogen receptor binding and oral antiestrogen activities.


Asunto(s)
Cromanos/química , Cromanos/farmacología , Moduladores de los Receptores de Estrógeno/química , Moduladores de los Receptores de Estrógeno/farmacología , Animales , Unión Competitiva , Cromanos/síntesis química , Evaluación Preclínica de Medicamentos , Estradiol/análogos & derivados , Estradiol/farmacología , Moduladores de los Receptores de Estrógeno/síntesis química , Femenino , Ratones , Ratones Endogámicos ICR , Modelos Moleculares , Conformación Molecular , Estructura Molecular , Tamaño de los Órganos/efectos de los fármacos , Ovariectomía , Receptores de Estrógenos/efectos de los fármacos , Receptores de Estrógenos/metabolismo , Estereoisomerismo , Relación Estructura-Actividad , Útero/anatomía & histología , Útero/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA